These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11306151)

  • 21. Monitoring late-onset toxicities in phase I trials using predicted risks.
    Bekele BN; Ji Y; Shen Y; Thall PF
    Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
    Chen Z; Krailo MD; Sun J; Azen SP;
    Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation trial designs based on a molecularly targeted endpoint.
    Hunsberger S; Rubinstein LV; Dancey J; Korn EL
    Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
    Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
    Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
    Rami A; DuBois SG; Campbell K
    Clin Trials; 2024 Apr; 21(2):211-219. PubMed ID: 37961910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
    Mick R; Ratain MJ
    J Natl Cancer Inst; 1993 Feb; 85(3):217-23. PubMed ID: 8423626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The i3+3 design for phase I clinical trials.
    Liu M; Wang SJ; Ji Y
    J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Competing designs for phase I clinical trials: a review.
    Rosenberger WF; Haines LM
    Stat Med; 2002 Sep; 21(18):2757-70. PubMed ID: 12228889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designs for phase I clinical trials with multiple courses of subjects at different doses.
    Fan SK; Wang YG
    Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-dimensional dose finding in discrete dose space.
    Wang K; Ivanova A
    Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in adaptive designs for Phase I/II dose-finding studies.
    Zohar S; Chevret S
    J Biopharm Stat; 2007; 17(6):1071-83. PubMed ID: 18027217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.